Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma
Status:
Terminated
Trial end date:
2009-12-25
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of LBH589B in adult patients with multiple
myeloma who have received at least two prior therapies and are refractory to their last
therapy. Patients must have received in prior therapy either bortezomib or lenalidomide